Drugs / BC106 insulin lispro
last change Dec 2015 re-read 2 minutes ago

BC106 insulin lispro

Developed for
type 1 diabetes mellitus
Investigated by
Adocia · Eli Lilly and Company

Trials 2 · a red edge is where a trial was stopped

201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02528396 Aug → Dec 2015 type 1 diabetes mellitus Adocia Completed No outcome recorded
Phase 1 NCT01638325 Jul → Sep 2012 Adocia Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as BC106 insulin lispro ClinicalTrials.gov intervention name — accepted as the source's own label NCT01638325
Known as BioChaperone insulin lispro ClinicalTrials.gov intervention name — accepted as the source's own label NCT02528396
Route Subcutaneous “Administered SC” NCT01638325